MRK•benzinga•
Biologics License Application For Daiichi Sankyo And Merck's Patritumab Deruxtecan Has Been Withdrawn Based On Topline Overall Survival (OS) Results From HERTHENA-Lung02 Trial Where OS Did Not Meet Statistical Significance
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 29, 2025 by benzinga